Prescribing pattern in Parkinson's disease: Are cost and efficacy overriding factors?

International Journal of Clinical Practice

Volumn 59, Issue 5, 2005, Pages 511-514

  Tan, Eng King ^a,b,c   Yeo, A P ^a   Tan, V ^a   Pavanni, R ^a,b,c   Wong, M C ^a,b,d  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

^b NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

^c Singapore Health Services   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Choice of drugs; Parkinson's disease; Prescribing pattern

Indexed keywords

ALPRAZOLAM; AMANTADINE; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; BENZODIAZEPINE DERIVATIVE; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLONAZEPAM; DECARBOXYLASE INHIBITOR; DIAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; LORAZEPAM; PERGOLIDE; PIRIBEDIL; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL SPECIALIST; MONOTHERAPY; PARKINSON DISEASE; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; CLINICAL PRACTICE; DECISION MAKING; ECONOMICS; MIDDLE AGED; NATIONAL HEALTH SERVICE; NEUROLOGY; SINGAPORE;

AGED; ANTIPARKINSON AGENTS; CHOICE BEHAVIOR; DRUG COSTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGY; PARKINSON DISEASE; PHYSICIAN'S PRACTICE PATTERNS; SINGAPORE; STATE MEDICINE;

EID: 27144477743     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2005.00426.x     Document Type: Article

References (19)

1. Tan EK. Parkinson's disease surgery: advances and future strategies. Int J Clin Pract 1999; 53: 623-6.
2. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993; 12: 195-208.
3. Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000; 55: 533-8.
4. Tan EK, Chai A, Zhao Y et al. Mitochondrial complex I polymorphism and cigarette smoking in Parkinson's disease. Neurology 2002; 59: 1288-9.
5. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589-98.
6. Tan EK, Jankovic J. Choosing dopamine agonists in Parkinson's disease. Clin Neuropharmacol 2001; 24: 247-53.
7. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 2001; 56: 11.
8. Tan EK, Ratnagopal P, Han SY, Wong MC. Piribedil and bromocriptine in Parkinson's disease: a single-blind crossover study. Acta Neurol Scand 2003; 107: 202-6.
9. Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol 2000; 57: 729-32.
10. Lim SH, Tan EK, Chen C. Pattern of anti-epileptic drug usage in a tertiary referral hospital in Singapore. Neurol J Southeast Asia 1997; 2: 77-85.
11. Leoni O, Martignoni E, Cosentino M et al. Drug prescribing patterns in Parkinson's disease: a pharmacoepidemiological survey in a cohort of ambulatory patients. Pharmacoepidemiol Drug Saf 2002; 11: 149-57.
12. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001; 57: 1392-6.
13. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 42: 1142-6.
14. Tan EK, Lum SY, Teoh ML et al. Evaluation of hypersomolence in PD: comparison with age and sex matched controls. Neurology 2002; 58: 465-8.
15. Vickrey BG, Gifford DR, Belin TR et al. Practice styles of US compared to UK neurologists. Neurology 1998; 50: 1661-8.
16. Grandas F, Kulisevsky J. Treatment of Parkinson's disease in Spain. Mov Disord 2003; 18: 87-9.
17. Davey P, Rajan N, Lees M, Aristides M. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model. Value Health 2001; 4: 308-15.
18. Rubenstein LM, DeLeo A, Chrischilles EA. Economic and health-related quality of life considerations of new therapies in Parkinson's disease. Pharmacoeconomics 2001; 19: 729-52.
19. Jost WH. Costs in the treatment of parkinsonism. J Neurol 2000; 247 (Suppl. 4): IV/31-3.